Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders

Trends in Neurosciences

Volumn 26, Issue 3, 2003, Pages 137-146

  Mattson, Mark P ^a   Shea, Thomas B ^b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY OF MASSACHUSETTS LOWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ADULTHOOD; ALZHEIMER DISEASE; AMINO ACID METABOLISM; AMYOTROPHIC LATERAL SCLEROSIS; CARDIOVASCULAR DISEASE; CELL DEATH; CLINICAL TRIAL; CYANOCOBALAMIN DEFICIENCY; DEGENERATIVE DISEASE; DEPRESSION; DIET SUPPLEMENTATION; DNA DAMAGE; DRUG EFFICACY; FOLATE METABOLISM; FOLIC ACID DEFICIENCY; GENETIC ANALYSIS; HOMEOSTASIS; HUMAN; HYPERHOMOCYSTEINEMIA; METHYLATION; NERVE CELL; NERVE CELL LESION; NERVE CELL PLASTICITY; NERVE GROWTH; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCHIZOPHRENIA; STROKE;

EID: 0037364417     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-2236(03)00032-8     Document Type: Review

References (104)

1. Scott J.M., Weir D.G. Folic acid, homocysteine and one-carbon metabolism: a review of the essential biochemistry. J. Cardiovasc. Risk. 5:1998;223-227.
2. Wainfan E., Poirier L.A. Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. Cancer Res. 52:1992;S2071-S2077.
3. Pogribny I.P., et al. Breaks in genomic DNA and within the p53 gene are associated with hypomethylation in livers of folate/methyl-deficient rats. Cancer Res. 55:1995;1894-1901.
4. Mudd S.H., Cantoni G.L. Biological transmethylation methyl-group neogenesis and other one carbon metabolic reactions dependent upon tetrahydrofolic acid. Florkin M., Stot E.H. Comprehensive Biochemistry. Vol. 15:1964;147-148 Elsevier.
5. Scott J.M. Folate-vitamin B12 interrelationships in the central nervous system. Proc. Nutr. Soc. 51:1992;219-224.
6. Ho P.I., et al. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J. Neurosci. Res. 70:2002;694-702.
7. Kruman I.I., et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J. Neurosci. 20:2000;6920-6926.
8. Djurhuus R., et al. Differential effects on growth, homocysteine, and related compounds of two inhibitors of S-adenosylhomocysteine catabolism, 3-deazaadenosine, and 3-deazaaristeromycin, in C3H/10T1/2 cells. Cancer Res. 49:1989;324-330.
9. Mosharov E., et al. The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. Biochemistry. 39:2000;13005-13011.
10. Finkelstein J.D. The metabolism of homocysteine, pathways and regulation. Eur. J. Pediatr. 157:(Suppl. 2):1998;S40-S44.
11. Shea, T.B. et al. (2002) Apolipoprotein E deficiency promotes increased oxidative stress and compensatory increases in antioxidants in brain tissue. Free Radic Biol Med. 33, 1115-1120.
12. Sirotnak F.M., Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Annu. Rev. Nutr. 19:1999;91-122.
13. Smithells R.W., et al. Vitamin deficiencies and neural tube defects. Arch. Dis. Child. 51:1976;944-950.
14. Kruman I.I., et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J. Neurosci. 22:2002;1752-1762.
15. Choi S.W., Mason J.B. Folate status: effects on pathways of colorectal carcinogenesis. J. Nutr. 132:2002;S2413-S2418.
16. Guerr-Shinohar E.M., et al. Relationship between total homocysteine and folate levels in pregnant women and their newborn babies according to maternal serum levels of vitamin B12. Br. J. Obstet.Gynaecol. 109:2002;784-791.
17. Hall C.A. Function of vitamin B12 in the central nervous system as revealed by congenital defects. Am. J. Hematol. 34:1990;121-127.
18. Lovblad K., et al. Retardation of myelination due to dietary vitamin B12 deficiency: cranial MRI findings. Pediatr. Radiol. 27:1997;155-158.
19. Thomas P.K., et al. Neurological involvement in hereditary transcobalamin II deficiency. J. Neurol. Neurosurg. Psychiatry. 45:1982;74-77.
20. Zhao Q., et al. Prenatal folic acid treatment suppresses acrania and meroanencephaly in mice mutant for the Cart1 homeobox gene. Nat. Genet. 13:1996;275-283.
21. Doolin M.T., et al. Maternal genetic effects, exerted by genes involved in homocysteine remethylation, influence the risk of spina bifida. Am. J. Hum. Genet. 71:2002;1222-1226.
22. Devlin A.M., et al. Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Hum. Mol. Genet. 9:2000;2837-2844.
23. Afman L.A., et al. Reduced vitamin B12 binding by transcobalamin II increases the risk of neural tube defects. Q. J. Med. 94:2001;159-166.
24. Mattson M.P. Apoptotic and anti-apoptotic synaptic signaling mechanisms. Brain Pathol. 10:2000;300-312.
25. Lipton S.A., et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. U. S. A. 94:1997;5923-5928.
26. Kilic G., et al. Single-channel currents of NMDA type activated by L- and D-homocysteic acid in cerebellar granule cells in culture. Neurosci. Lett. 141:1992;231-235.
27. Flott-Rahmel B., et al. Homocysteic and homocysteine sulphinic acid exhibit excitotoxicity in organotypic cultures from rat brain. Eur. J. Pediatr. 157:1998;S112-S117.
28. Otis L.C., et al. Folic acid has a disinhibitory action in the rat hippocampal slice preparation. Brain Res. 346:1985;281-286.
29. Piedrahita J.A., et al. Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nat. Genet. 23:1999;228-232.
30. Shields D.C., et al. The 'thermolabile' variant of methylenetetrahydrofolate reductase and neural tube defects: an evaluation of genetic risk and the relative importance of the genotypes of the embryo and the mother. Am. J. Hum. Genet. 64:1999;1045-1055.
31. Botto L.D., Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies, a HuGE review. Am. J. Epidemiol. 151:2000;862-867.
32. Engbersen A.M., et al. Thermolabile 5-10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am. J. Hum. Genet. 56:1995;142-150.
33. Frosst P., et al. A candidate genetic risk factor for vascular disease, a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10:1995;111-113.
34. Arruda V.R., et al. The mutation Ala677-Val in the methylene tetrahydrofolate reductase gene, a risk factor for arterial disease and venous thrombosis. Thromb. Haemost. 77:1997;818-821.
35. Stern L.L., et al. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol. Biomarkers Prev. 9:2000;849-853.
36. Haworth J.C., et al. Symptomatic and asymptomatic methylenetetrahydrofolate reductase deficiency in two adult brothers. Am. J. Med. Genet. 45:1993;572-576.
37. Watkins D., Rosenblatt D.S. Functional methionine synthase deficiency (cb1E and cb1G), clinical and biochemical heterogeneity. Am. J. Med. Genet. 34:1989;427-434.
38. Ma J., et al. A polymorphism of the methionine synthase gene, Association with plasma folate, vitamin B12, homocystine, and Colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 8:1999;825-829.
39. Mudd S.H., et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am. J. Hum. Genet. 37:1985;1-31.
40. Djurhuus R., et al. Differential effects on growth, homocysteine, and related compounds of two inhibitors of S-adenosylhomocysteine catabolism, 3-deazaadenosine, and 3-deazaaristeromycin, in C3H/10T1/2 cells. Cancer Res. 49:1989;324-330.
41. Ho P.I., et al. Homocysteine potentiates beta-amyloid neurotoxicity, role of oxidative stress. J. Neurochem. 78:2001;249-253.
42. Surtees R., et al. Cerebrospinal fluid and plasma total homocysteine and related metabolites in children with cystathionine beta-synthase deficiency, the effect of treatment. Pediatr. Res. 42:1997;577-582.
43. Al-Gazali L.I., et al. Abnormal folate metabolism and genetic polymorphism of the folate pathway in a child with Down syndrome and neural tube defect. Am. J. Med. Genet. 103:2001;128-132.
44. James S.J., et al. Abnormal folate metabolism and mutation in the methylenetetrahydrofolate reductase gene may be maternal risk factors for Down syndrome. Am. J. Clin. Nutr. 70:1999;495-501.
45. Pogribna M., et al. Homocysteine metabolism in children with Down syndrome, in vitro modulation. Am. J. Hum. Genet. 69:2001;88-95.
46. Walter J.H., et al. Strategies for the treatment of cystathionine beta-synthase deficiency, The experience of the Willink Biochemical Genetics Unit over the past 30 years. Eur. J. Pediatr. 157:(Suppl. 2):1998;S71-S76.
47. Ronge E., Kjellman B. Long term treatment with betaine in methylenetetrahydrofolate reductase deficiency. Arch. Dis. Child. 74:1996;239-241.
48. Knopman D., Patterson M. An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients. Alzheimer Dis. Assoc. Disord. 15:2001;162-165.
49. McKeever M.P., et al. Betaine-homocysteine methyltransferase organ distribution in man, pig and rat and subcellular distribution in the rat. Clin. Sci. 81:1991;551-556.
50. Agamanolis D.P., et al. An ultrastructural study of subacute combined degeneration of the spinal cord in vitamin B12-deficient rhesus monkeys. J. Neuropathol. Exp. Neurol. 37:1978;273-299.
51. Scott J.M., et al. Pathogenesis of subacute combined degeneration: a result of methyl group deficiency. Lancet. 2:1981;334-337.
52. Selhub J., Miller J.W. The pathogenesis of homocysteinemia, interruption of the coordinate regulation by S-adenosylmethionine of theremethylation and transsulfuration of homocysteine. Am. J. Clin. Nutr. 55:1992;131-138.
53. Davey G.P., et al. Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. J. Biol. Chem. 273:1998;12753-12757.
54. Mattson M.P., et al. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann. New York Acad. Sci. 893:1999;154-175.
55. Grunewald T., Beal M.F. Bioenergetics in Huntington's disease. Ann. New York Acad. Sci. 893:1999;203-213.
56. Huang R.F., et al. Folate depletion and elevated plasma homocysteine promote oxidative stress in rat livers. J. Nutr. 131:2001;33-88.
57. Upchurch G.R., et al. Homocysteine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J. Biol. Chem. 272:1997;17012-17017.
58. Henning S.M., et al. Vitamins C, E and A and heme oxygenase in rats fed methyl/folate-deficient diets. Free Radic. Biol. Med. 23:1997;936-942.
59. Huang H.Y., et al. Effects of vitamin C and vitamin E on in vivo lipid peroxidation: results of a randomized controlled trial. Am. J. Clin. Nutr. 76:2002;549-555.
60. Shea, T.B. and Rogers, E. (2002) Folate quenches oxidative damage in brains of apolipoprotein E-deficient mice: augmentation by vitamin E. Mol. Brain Res. 108, 1-6.
61. Doshi S.N., et al. Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide. Arterioscler. Thromb. Vasc. Biol. 21:2001;1196-1202.
62. Cantoni G.L. The centrality of S-adenosylhomocysteine in the regulation of the biological utilization of S-adenosylmethionine. Borchardt C., Ueland P.M. Biological Methylation and Drug Design, Experimental and Clinical Roles of SAM. 1986;227-237 Humana Press.
63. Hankey G.J., Eikelboom J.W. Homocysteine and stroke. Curr. Opin. Neurol. 14:2001;95-102.
64. Seshadri S., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. New Engl. J. Med. 346:2002;476-483.
65. Clarke R., et al. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch. Neurol. 55:1998;1449-1455.
66. Miller J.W. Homocysteine and Alzheimer's disease. Nutr. Rev. 57:1999;126-129.
67. Gottfries C.G., et al. Early diagnosis of cognitive impairment in the elderly with the focus on Alzheimer's disease. J. Neural Transm. 105:1998;773-786.
68. McCaddon A., et al. Total serum homocysteine in senile dementia of Alzheimer type. Int. J. Geriatr. Psychiatry. 13:1998;235-239.
69. Joosten E., et al. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J. Gerontol. A Biol. Sci. Med. Sci. 52:1997;M76-M79.
70. Lehmann M., et al. Identification of cognitive impairment in the elderly, homocysteine is an early marker. Dement. Geriatr. Cogn. Disord. 10:1999;12-20.
71. Snowdon D.A., et al. Serum folate and the severity of atrophy of the neocortex in Alzheimer disease, findings from the Nun Study. Am. J. Clin. Nutr. 71:2000;993-998.
72. Serot J.M., et al. CSF-folate levels are decreased in late-onset AD patients. J. Neural Transm. 108:2001;93-99.
73. Bottiglieri T., et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia, effects of treatment with parenteral and oral S-adenosylmethionine. J. Neurol. Neurosurg. Psychiatry. 53:1990;1096-1098.
74. Iannello R.C., et al. Oxidative stress and neural dysfunction in Down syndrome. J. Neural Transm. Suppl. 57:1999;257-267.
75. Mattson M.P. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77:1997;1081-1132.
76. Growdon J.H. Incorporating biomarkers into clinical drug trials in Alzheimer's disease. J. Alzheimers Dis. 3:2001;287-292.
77. White A.R., et al. Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary cultures, possible risk factors in the Alzheimer's-type neurodegenerative pathways. J. Neurochem. 76:2001;1509-1520.
78. Fuchs D., et al. Is hyperhomocysteinemia due to the oxidative depletion of folate rather than to insufficient dietary intake? Clin. Chem. Lab. Med. 39:2001;691-694.
79. 12 deficiency and Alzheimer disease. Neurology. 58:2002;1395-1399.
80. Candito M., et al. Cerebral vascular complication of hyperhomocysteinemia. Controlling thromboembolic complications with folates. Presse Med. 26:1997;1289-1291.
81. Sai X., et al. Endoplasmic reticulum stress-inducible protein, Herp, enhances presenilin-mediated generation of amyloid β-protein. J. Biol. Chem. 277:2002;12915-12920.
82. Chan S.L., et al. Herp stabilizes neuronal calcium homeostasis and mitochondrial function during endoplasmic reticulum stress: implications for neurodegenerative disorders. Soc. Neurosci. Abstr. 32:2002;19312.
83. Eto K., et al. Brain hydrogen sulfide is severely decreased in Alzheimer's disease. Biochem. Biophys. Res. Commun. 293:2002;1485-1488.
84. Morrison L.D., et al. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J. Neurochem. 67:1996;1328-1331.
85. Ramassamy C., et al. Oxidative damage and by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic. Biol. Med. 27:1999;544-553.
86. Pedersen W.A., et al. A mechanism for the neuroprotective effect of apolipoprotein E: isoform-specific modification by the lipid peroxidation product 4-hydroxynonenal. J. Neurochem. 74:2000;1426-1433.
87. Nishiyama M. Apolipoprotein E, methylenetetrahydrofolate reductase (MTHFR) mutation and the risk of senile dementia-an epidemiological study using the polymerase chain reaction (PCR) method. J. Epidemiol. 10:2000;163-172.
88. Lievre V., et al. Intracellular generation of free radicals and modifications of detoxifying enzymes in cultured neurons from the developing rat forebrain in response to transient hypoxia. Neuroscience. 105:2001;287-297.
89. Blandini F., et al. Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease. Clin. Chem. 47:2001;1102-1104.
90. Yasui K., et al. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology. 55:2000;437-440.
91. Liu X.X., et al. Effects of L-dopa treatment on methylation in mouse brain: implications for the side effects of L-dopa. Life Sci. 66:2000;2277-2288.
92. Duan W., et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J. Neurochem. 80:2002;101-110.
93. Reynolds E.H., et al. Folate deficiency in depressive illness. Br. J. Psychiatry. 117:1970;287-292.
94. Alpert J.E., et al. Nutrition and depression: focus on folate. Nutrition. 16:2002;544-546.
95. Gray G.E. Nutrition and dementia. J. Am. Diet. Assoc. 89:1989;1795-1802.
96. Bottiglieri T., et al. Homocysteine, folate, methylation, and monoamine metabolism in depression. J. Neurol. Neurosurg. Psychiatry. 69:2000;228-232.
97. Botez M.I., et al. Effect of folic acid and vitamin B12 deficiencies on 5-hydroxyindoleacetic acid in human cerebrospinal fluid. Ann. Neurol. 12:1982;479-484.
98. Shiloh R., et al. Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression-preliminary open-label trial. Harefuah. 140:2001;369-373.
99. Susser E., et al. Schizophrenia and impaired homocysteine metabolism: a possible association. Biol. Psychiatry. 44:1998;141-143.
100. Regland B., et al. Homocysteinemia is a common feature of schizophrenia. J. Neural Transm. Gen. Sect. 100:1995;165-169.
101. Godfrey P.S., et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 336:1990;392-395.
102. Regland B., et al. Homozygous thermolabile methylenetetrahydrofolate reductase in schizophrenia-like psychosis. J. Neural Transm. 104:1997;931-941.
103. Lowe T.L. Folic acid and B12 in autism and neuropsychiatric disturbances of childhood. J. Am. Acad. Child Psychiatry. 20:1981;104-111.
104. Brattstrom L., et al. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. Br. Med. J. 316:1998;894-898.